e world’s rst polymer-free stent with BA9 ™ e world’s rst polymer-free stent with BA9 ™ Ordering Information Stent Length (mm) Stent Diameter (mm) 1. Clinical studies exploring this potential are in progress 2. In vivo data shows that approximately 2% of BA9 remains on the stent after 28 days. Data on le at Biosensors International 3. Adapted from Grube E., oral presentation TCT 2010 BioFreedom™ drug-coated stent is CE Mark approved. CAUTION: e law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. BioFreedom, Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd. in the United States and other countries. All cited trademarks are the property of their respective owners. Not available for sale in the United States and certain other countries. © 2013 Biosensors International Group, Ltd. All rights reserved. BIOSENSORS INTERVENTIONAL TECHNOLOGIES PTE LTD

Expanding the therapeutic horizon for physicians Changing the script Drug Eluting Stents (DES) are proven to reduce the risk of restenosis and improve outcomes for patients with more complex coronary disease. However, in certain patients where there is a requirement to avoid prolonged Dual Anti-Platelet erapy (DAPT), Bare Metal Stents (BMS) may be preferred. BioFreedom ™, as a Drug-Coated Stent (DCS), combines the advantages of both DES and BMS. It delivers an eective anti-restenotic therapy with Biolimus A9 ™, and may shorten the required DAPT 1 regime. Increasing safety and ecacy Following...